Irish Cancer Society Research Fellowship awarded to Amanda Tivnan

Congratulations to Dr. Amanda Tivnan from the Centre for Systems Medicine, Royal College of Surgeons in Ireland. She is awarded a Research Fellowship by the Irish Cancer Society.

AmandaTivnan receives Irish Cancer Society Research Award

Dr Amanda Tivnan with Professor John Fitzpatrick, Head of Research, Irish Cancer Society, Mr Dermot Breen, Tesco, and Ray D’Arcy, Broadcaster at Today FM receiving the Irish Cancer Society Research Fellowship Award Certificate

Dr. Amanda Tivnan at the Irish Cancer Society Research Fellows and Scholars Awards Ceremony in Dublin at which six new cancer research grants were awarded, said, “Although any form of brain cancer is serious, diagnosis of a patient with glioblastoma multiforme (GBM) currently holds the worst outcome, with an average survival of only 12-15 months. It is a highly aggressive brain cancer due to increased numbers of ‘pumps’, called transporters, on the cancer cells surface that rapidly remove the chemotherapy from the cell, not allowing it enough time to act and kill the brain cancer.”

“My research aims at targeting these pumps, so allowing the chemotherapy a longer time within the cancer cells and hopefully increasing its killing abilities. It will also focus on developing novel technologies to remove these pumps from the cancer cells, and then reassessing the response of these glioblastoma cells to chemotherapy, providing us with hope for patient survival in the future.”

Speaking at the Ceremony, Prof. John Fitzpatrick, Head of Research, Irish Cancer Society said, “The Irish Cancer Society’s vision for cancer research is based on achieving world-class discoveries across all cancer types to improve outcomes for the thousands of patients that are diagnosed each year in Ireland. We are extremely proud to announce our next round of Fellows and Scholars that will join the battle against cancer by applying their great knowledge and skills- to finding new ways to improve patient outcomes.”

“Over the past 50 years, the Irish Cancer Society has contributed €33 million to advance high-quality cancer research in Ireland. This funding has gone towards research grants, such as the Scholarship and Fellowship programmes, and the country’s first Collaborative Cancer Research Centre BREAST-PREDICT, which aims to predict the best treatment options for breast cancer patients. None of this would have been made possible without the general public’s ongoing support and commitment to fundraising for cancer research.” The Society’s Fellows and Scholars are also supported by the Tesco Charity of the Year Partnership 2010-2011 and the Movember Foundation.

Women race to pay tribute to friend who died of brain cancer and raise almost €30K for Irish Cancer Society research grants

An inspiring group of 47 women self-titled the Rainbow Runners raced to the finish line at the Flora Women’s Mini Marathon this year to pay tribute to their dear friend Gayle Warnock, who died from an inoperable brain tumour in 2012 aged 38, and raised almost €30K for Irish Cancer Society Research.

Caroline Reay said the women had chosen the Irish Cancer Society “as Gayle wanted to run the marathon herself, and donate the money to the Society to encourage new research discoveries that might one day benefit thousands of patients battling cancer in Ireland.” Their contribution will go towards the Irish Cancer Society’s total €33 million investment in cancer research over the past 50 years, making them Ireland’s largest voluntary funder of cancer research.

The Society’s Research Fellows and Scholars awards are designed to foster home-grown cancer research talent in Ireland and to ensure new research projects are commenced in a range of cancers including brain tumours, colorectal, oesophageal, prostate and breast cancers. The research projects span a wide range of research areas and will investigate a number of potentially important topics, such as novel technologies that could increase the length of time that chemotherapy can act inside cancer cells, novel targets to develop drugs against and broadening treatment options.

Workshop on light sheet fluorescence microscopy was full success

CSM successfully hosted the first Irish/UK light sheet fluorescence microscopy workshop organized by Dr Emmanuel G. Reynaud (UDC) and Dr Heiko Dussmann (RCSI). Lectures given by Malte Wachsmuth (21st Nov 2013), Bill Chaudry, Chris Power, Ellen Barker, and Emmanuel Reynaud drew a clear picture in the morning sessions (25th Nov 2013) of the new dimensions of imaging possibilities, which were then demonstrated in the hands on training sessions in the afternoon.

Thank you to the speakers agreeing to offer presentations for download:

Here are some impressions of the event:

Seminar: Fiona Ginty, GE Global Research Centre

Dr. Fiona Ginty

Principal Scientist, Life Sciences and Molecular Diagnostics, General Electric Global Research Center

Tumor heterogeneity revealed using high-order in situ multiplexing

The Centre for Systems Medicine is pleased to announce a seminar by Dr. Fiona Ginty from General Electric Global Research Center, Niskayuna, NY.

Abstract: Protein analysis in formalin-fixed, paraffin-embedded tissues is typically limited to 1-2 markers per tissue slide using chromogenic stains, or up to four markers using immunofluorescence. The increasing demands on tissue for predictive and prognostic biomarker testing presents significant challenges for pathologists and oncologists to ensure that the most important markers are selected for patient care. Coupled with this, tumor and cellular heterogeneity may confound genomic results. To address these challenges, GE scientists have developed a multiplexed immunofluorescence technology that allows measurement of up to 60 markers at single cell level in a 5 um FFPE tissue section (MultiOmyx™). DNA FISH analysis may also be conducted on the same sample, following multiplexed protein analysis. Image processing and visualization tools allow interactive assessment cellular biomarkers in context of tumor histology and microenvironment.  In addition to sparing precious sample, multiplexed analysis allows quantitation and visualization of extensive biomarker heterogeneity within the tumor, stroma, blood vessels and other cellular features. This platform will provide new opportunities for redefining and understanding biological mechanisms for basic and drug discovery research.

Please see also the publication Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue PNAS 2013 110 (29) 1198211987; published ahead of print July 1, 2013

The talk is free and open to everyone and will be held in Houston Lecture Theater, RCSI on the 16th of December 2013 at 4 pm.

This seminar is supported by the RCSI seed fund program.